OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients



BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion



Maintenance or increases...

Related Keywords

Israel ,Jerusalem ,Israel General ,United States ,American ,David Telander ,Brianm Culley ,Roche Group ,Genentech ,Foundation Fighting Blindness ,Exchange Commission ,Oregon Health Science University Casey Eye Institute ,Retinal Consultants Medical Group ,Eterna Therapeutics Inc ,Lineage Cell Therapeutics Inc ,Lineage Cell Therapeutics ,Gene Therapy Innovation ,Oregon Health ,Science University Casey Eye ,Retinal Pigment Epithelium ,Cell Therapy ,Geographic Atrophy ,Early Treatment Diabetic Retinopathy Study ,Retinal Cell ,Gene Therapy Innovation Summit ,Opregen Phase ,Cell Therapeutics ,Eterna Therapeutics ,Annual Report ,